Northwestern: lung transplants extend stage 4 cancer survival
Get the Health newsletter
Daily health & science — research, biotech, public health, the studies worth knowing. Free.
- Northwestern Medicine reported in JAMA that 17 stage 4 lung cancer patients who received double lung transplants fared better than 81 comparable patients who stayed on standard chemotherapy, immunotherapy, or radiation, out of 404 patients tracked overall.
- Through June 2025, all 17 transplant recipients had survived one year, compared with 88% one-year survival among non-cancer transplant patients; by January 2026 there were four cancer recurrences and two non-cancer deaths (infection, blood clot), while 74 of 81 standard-care patients saw their cancers progress.
- Lead author Ankit Bharat, chief of thoracic surgery at Northwestern, said the protocol grew out of the team's 2020 first lung transplant in a Covid patient, applying lessons from removing heavily damaged lungs to cases of treatment-resistant cancer confined to the lungs.
- In a JAMA editorial, Ece Cali Daylan and Ramaswamy Govindan of Washington University and Siteman Cancer Center flagged the ethical stakes of a 'zero-sum' organ system and called for larger, randomized studies before adoption; Bharat countered that the early data show no meaningful outcome difference vs. non-cancer recipients.
- The eligible pool is small — an estimated 300 US patients per year with stage 4 non-small cell lung cancer confined to the lungs, like NASA software engineer Jodi Graf, 61, who received her transplant 24 hours after listing at Northwestern.
- Bharat noted the hospital's average lung transplant wait is now about three days, driven by newer technologies and improved donation practices that expand organ availability for this and other recipients.
Why it matters: If confirmed in larger studies, the protocol would re-open transplantation as an option for roughly 300 U.S. patients annually whose stage 4 lung cancer has not metastasized — currently excluded due to high historical recurrence and low survival. The ethical counterweight is real: transplant organs remain a zero-sum resource, and JAMA editors insist randomized evidence must come before wider adoption. The early numbers — 100% one-year survival and a trend toward better outcomes than non-cancer recipients — are what makes the debate urgent.
